Medicare billing address
CMS Medicare provider billing file
6900 Pearl Rd2Nd Floor
Middleburg Heights, OH 44130
CMS public data · NPI 1265400592
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Lawrence A Gervasi, MD
Specialty
Credential
MD
NPI
1265400592
Primary source state
OH
Data retrieval date
July 27, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Lawrence A Gervasi, MD from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
6900 Pearl RdCMS Doctors & Clinicians file
6900 Pearl RdIn the 2024 CMS provider billing file, this NPI had 853 Medicare beneficiaries and 12,115 total services. The average beneficiary age was 76, and the average HCC risk score was 1.2.
Total Medicare allowed amount
$451,724.74
Total Medicare payment amount
$345,494.66
Medicare beneficiaries
853
Total services
12,115
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
75%
CMS beneficiary-panel share
Ischemic heart disease
37%
CMS beneficiary-panel share
Diabetes
29%
CMS beneficiary-panel share
Chronic kidney disease
26%
CMS beneficiary-panel share
Atrial fibrillation
22%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, denosumab, 1 mg | 2,580 | $24.70 |
| Bcg live intravesical instillation, 1 mg | 2,525 | $2.87 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 827 | $120.16 |
| Manual urinalysis test with examination using microscope, automated | 790 | $3.09 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 539 | $59.20 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 377 | $175.35 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 360 | $58.55 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 271 | $85.49 |
| Insertion of needle into vein for collection of blood sample | 221 | $8.65 |
| Psa (prostate specific antigen) measurement, total | 216 | $17.94 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1265400592. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Tamsulosin Hcl | Tamsulosin Hcl | 1,103 | 2,686.4 | $17,138.36 |
| 2 | Finasteride | Finasteride | 670 | 1,844 | $7,251.88 |
| 3 | Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 368 | 374 | $3,014.94 |
| 4 | Erleada | Apalutamide | 190 | 200 | $2,989,034.93 |
| 5 | Xtandi | Enzalutamide | 178 | 178 | $2,451,209.98 |
| 6 | Oxybutynin Chloride Er | Oxybutynin Chloride | 155 | 371.7 | $5,081.67 |
| 7 | Ciprofloxacin Hcl | Ciprofloxacin Hcl | 142 | 144 | $764.24 |
| 8 | Nubeqa | Darolutamide | 135 | 136 | $1,826,811.31 |
| 9 | Levofloxacin | Levofloxacin | 110 | 110 | $116.43 |
| 10 | Alfuzosin Hcl Er | Alfuzosin Hcl | 63 | 163 | $1,391.14 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
Baylor College Of Medicine
Graduation year
1985
Group/practice field
Southwest Urology, Llc
Telehealth reported
Yes
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.